New Ky. law limits prescriptions for certain pain meds to 3-day supply

New Ky. law limits prescriptions for certain pain meds to 3-day supply

http://www.wdrb.com/story/35790831/new-ky-law-limits-prescriptions-for-certain-pain-meds-to-3-day-supply

LOUISVILLE Ky. (WDRB) — A new law that limits how much pain medicine doctors can prescribe in Kentucky is now in effect. 

The new law that took effect Thursday is designed to help fight the opioid epidemic that’s sweeping the nation. Under the new law, prescription painkillers will be limited to a 3-day supply in an effort to prevent abuse. 

The idea behind HB 333 is to prevent extra opioid pain pills from entering the illegal drug market. The bill underwent intense debate by Kentucky lawmakers before it was passed earlier this year. 

The bill’s sponsors say the goal is to get drugs like fentanyl and carfentanyl off the streets and out of the hands of drug traffickers. Penalties for anyone caught trafficking the drugs are now elevated to a Class C Felony for a first offense. 

The biggest concern over the new law centers on the 3-day pain pill limit, which prohibits doctors from issuing a prescription for more than the three days for Schedule II narcotics like OxyContin. 

Some patients who truly need the medication say the law makes it too difficult for them to get pain medication for legitimate reasons. 

The law does include exceptions for cancer patients, people diagnosed with chronic pain and patients receiving end-of-life care.

  How bright does a politician have to be to come to the conclusion that by limiting the legal prescribing of opiates will somehow stop the flow of ILLEGAL OPIATES from being on the street ?

 

A new addition to our family

I know that my blog has been very quite for a few days..  Last Thursday we drove from our Indiana home to Durham, NC (550 miles) to visit with our Daughter and grandson and to celebrate our Daughter’s birthday – which is actually today (Aug 15). My laptop and IPad remained safely in my backpack.. I didn’t even attempt to get them out…  I tried to scan my emails using my phone and “trashing” the emails that were more or less spam..

I went “cold turkey” and really didn’t have any side effects.. of course keeping up with a 10 y/o grandson.. there was no time to think about anything… we were either “going” or trying to “recover” from all the “going”

Monday we took off for our beach home – 800 miles –  This sweet  little girl ( 7 y/o Shih Tzu name Cuddles) in the picture, lost her “forever home” on July 15th when her Daddy (James) died.

None of his adult children wanted her and before she could be tossed into the “recycle bin” we reached out to his “girl friend” offering to “rescue her”.

We had been friends with her Daddy and her Mommy – who died in May 2011 – for over two decades.

This is not the best picture of her, she apparently doesn’t like to have her picture taken… and there are really two eyes in that “black mask” on her face, but today we “officially” adopted her and she is in her last “forever home”. And she can continue to live in the style which she had become accustomed to.

We still have to find out what kind of “traveler” she is… since James did not travel with her except to the vet and groomer and within a week we will be head back to Indiana with another long (650 mile) trip.  It may end up being a new experience for all of us 🙂

 

 

Zynerba Shares Plunge as Cannabis-Based Epilepsy Gel Fails Study

Zynerba Shares Plunge as Cannabis-Based Epilepsy Gel Fails Study

https://www.doximity.com/doc_news/v2/entries/8719011

Zynerba Pharmaceuticals Inc’s stock lost more than half its value on Monday after the U.S. drug developer said its synthetic cannabis-based gel for epilepsy failed a mid-stage study.

Zynerba’s gel contains a synthetically processed formulation of cannabidiol (CBD), a non-psychoactive component of the cannabis plant.

Although many U.S. states have sanctioned the medical and/or recreational use of cannabis, drugs derived from the plant could take longer than others to hit the market.

Under U.S. federal law, marijuana is considered a dangerous substance with no medicinal value, making additional approvals for marijuana-derived treatments necessary prior to launch.

Two doses of Zynerba’s ZYN002 gel were tested against a placebo in the study.

Neither dose induced a statistically significant improvement in seizure frequency versus the placebo in patients who were already on up to three anti-epileptic medications.

The 188-patient study comprised adults suffering from epilepsy with partial seizures, which occurs when epileptic activity takes part in a localized part of the brain.

FDA Warns Against Use of Any Liquid Product From PharmaTech

FDA Warns Against Use of Any Liquid Product From PharmaTech

http://www.medscape.com/viewarticle/883981

Clinicians and patients should not use any liquid product manufactured by Pharma Tech LLC and distributed by Rugby Laboratories because of Burkholderia cepacia contamination and the potential for severe patient infection, the US Food and Drug Administration (FDA) advised today in a safety communication. 

Dicto Liquid. Photo courtesy of the FDA

On August 3, Rugby Laboratories, of Livonia, Michigan, announced a voluntary recall of two oral liquid docusate products — Diocto Liquid and Diocto Syrup — manufactured by PharmaTech, of Davie, Florida.

“Additional liquid drug products manufactured by PharmaTech might also be affected. Such products might have been labeled and distributed by Rugby and other companies. Any company that purchased liquid products manufactured by PharmaTech should immediately quarantine material under their control and contact the local FDA pharmaceutical recall coordinator,” the FDA advised.

 

The agency acknowledges that it might be tough to determine the manufacturer because these liquid products are not labeled with a PharmaTech label. Healthcare facilities and pharmacies that think they might have liquid PharmaTech drug products, especially oral liquid docusate drug products, should check with their supplier to determine who manufactured the product, the FDA said. 

According to the FDA, laboratory testing of PharmaTech’s oral liquid docusate, conducted by the Centers for Disease Control and Prevention (CDC), found a strain of B cepacia, which has been linked to recent infections in patients.

In 2016, the CDC and the FDA advised against using any liquid docusate drug products.

An investigation into a 2016 multistate outbreak identified B cepacia in more than 10 lots of oral liquid docusate sodium manufactured by PharmaTech, which was linked to patient infections that required intensive medical treatment. The 2016 investigation also detected B cepacia in the water system used to manufacture the product, the FDA said.

This year, the agency said it has received reports of “several adverse events” related to oral liquid docusate sodium products. 

Healthcare professionals are encouraged to report problems related to these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program

Independent Pharmacies, Coupons Result in Big Savings on Drugs

Independent Pharmacies, Coupons Result in Big Savings on Drugs

www.pharmacyschool.usc.edu/price-shopping-for-prescription-medications-can-yield-considerable-cost-savings-usc-study-finds/

After finding that prices for some common antibiotics can vary in price by up to $100 in one metropolitan area, USC experts suggest that patients could save money by shopping for their drugs online or in independent pharmacies. However, few Americans actively comparison shop for health care, according to a separate study by USC and Harvard Medical School researchers.

Uninsured patients or those with limited prescription drug coverage can save significant money by buying their drugs at independent pharmacies instead of big box, grocery or chain drug stores and by using discount coupons, USC researchers have found.

The cash price for a commonly prescribed generic antibiotic can vary, on average $52, within a single ZIP code, according to the study published in the American Journal of Managed Care.

In a survey of 535 pharmacies in Los Angeles County’s highest and lowest-income ZIP codes, USC researchers found that the prices were lowest at independent pharmacies and when using online coupons compared to the prices found at grocery, big-box or chain stores. The researchers said they would expect similar results in other areas of the country.

The study indicates that patients can potentially save significant amounts simply by comparison shopping within their neighborhood or by using discount coupons available online.

“Consumers typically know the price of a product and have some information about its quality before purchasing. That’s rarely the case in health care,” said lead author Geoffrey Joyce, director of health policy at the USC Leonard D. Schaeffer Center for Health Policy and Economics and associate professor at the USC School of Pharmacy.

A separate study released Monday in the journal Health Affairs further confirmed that health care price shopping is uncommon. USC Schaeffer Center and Harvard Medical School researchers found that few Americans actively obtain price information before going to the doctor.

2 antibiotics, 82 ZIP codes

The research team called pharmacies in the highest and lowest income ZIP codes in Los Angeles County between July and August 2014. Explaining that they were calling on behalf of an uninsured patient, the researchers asked for the cash price for two commonly prescribed generic antibiotics, levofloxacin and azithromycin, which treat community-acquired pneumonia.

They then analyzed variation in the price quoted across and within 82 ZIP codes, as well as by type of pharmacy, including chain drug stores, independent pharmacies, grocery stores, or big-box stores. Researchers also obtained prices for the two medications from GoodRx, a popular online service that aggregates discounts and coupons.

In low-income areas, the price for levofloxacin ranged from a low of $4 to a maximum price of $149. In high-income areas the range was $5 to $229. The patterns were similar for azithromycin, though on a smaller scale: the price range was $2 to $26 in low-income ZIP codes, and $4 to $30 in the high-income areas.

Additionally, Joyce and his colleagues found the type of pharmacy affected the price variation. The average price for levofloxacin at an independent pharmacy or purchased with a GoodRx coupon cost less than half the price quoted at a big-box store and less than one fourth the discounted price at a chain drug store.

Overall, the average price difference between the highest and lowest-cost pharmacies in a ZIP code was more than $100 for levofloxacin and $30 for azithromycin.

“When physicians learn about the magnitude of price variation they will be stunned,” said co-author Sanjay Arora, a physician and associate professor of clinical emergency medicine at the Keck School of Medicine of USC. “When a patient says they could not afford a prescription medication, we assume it is just an expensive medication when in fact they may have just gone to an expensive retail outlet.”

With such wide variations in prices, price-shopping for prescription medications can yield considerable cost savings. “The extent of price variation within a market is an implicit measure of the benefit of price shopping,” Joyce says.

Consumers need transparency

Though policymakers have latched on to the idea of consumer-driven healthcare as a way to reduce rising costs, in practice it has proven challenging to realize. This is due in part to the lack of transparency in pricing medical services as well as the challenge of assessing quality.

In terms of quality, prescription drugs are much easier to understand- consumers know that no matter where they fill their prescription, they are going to get the same medicine.

“The wide variation in prices shows that pharmacies are exploiting the fact that sick patients do not have the time to shop around for their drugs,” explained Neeraj Sood, a co-author on the study and professor at the USC Price School of Public Policy and director of research at the USC Schaeffer Center. “Our study suggests that consumers can do two things to save money: shop online at websites like GoodRx or go to your local independent pharmacist.”

Though the uninsured rate has improved with the passage of the Affordable Care Act, many individuals still pay the cash price for their prescription drugs. This includes more than 32 million consumers who remain uninsured as well as the increasing number of individuals who have high-deductible plans with limited prescription benefits.

The study found that the amount of money that consumers could save is no small sum, especially for low-income consumers who are also more likely to be uninsured or in high-deductible plans.

“Education on this issue should become part of routine discharge planning,” noted Arora.

Policies that encourage greater price transparency as well as campaigns to educate consumers about the potential for price variation would go a long way towards reducing this sort of excess spending.

Sophie Terp, assistant professor at the Keck School of Medicine, also co-authored the study.

Promise tracker: Is Trump keeping his word on opioids?

Promise tracker: Is Trump keeping his word on opioids?

http://www.cbsnews.com/news/promise-tracker-is-trump-keeping-his-word-on-opioids/

On October 15, 2016, then-presidential candidate Donald Trump outlined steps his administration would take to combat the opioid crisis. Below is a check-up on the 12 promises he made in that speech. We will update this list as new steps are taken by the administration.

The problem: Two million Americans are addicted to prescription opioids, 600,000 are addicted to heroin and some estimates say over 59,000 people died from drug overdose deaths in 2016.  

1. We will stop the flow of illegal drugs into the country.  The number of illegal border crossings has dropped by more than half in the last year. In June, there were 21,659 illegal crossings compared to 45,722 in the same month last year, according to the US Customs and Border Protection statistics. However, it’s unclear if that decline has made a difference in the amount of heroin or fentanyl coming across the border. The number of opioid deaths rose in the first nine months of 2016, according to the National Center for Health Statistics. There are no figures for 2017 yet. 

2. We are also going to put an end to “sanctuary cities,” which refuse to turn over illegal immigrant drug traffickers for deportation. The administration has aggressively sought to end the designation of sanctuary cities and that effort has now been challenged in a lawsuit.

3. We will dismantle the illegal immigrant cartels and violent gangs, and we will send them swiftly out of our country. While Immigration, Customs and Enforcement agency (ICE) arrests have risen by 37 percent, actual deportations have fallen during the Trump Administration, according to the Department of Homeland Security (DHS). The head of ICE has pointed to a backlog in the Justice Department’s Executive Office for Immigration Review as a cause of the lack of deportations. 

4. We will aggressively prosecute traffickers of illegal drugs, and provide law enforcement and prosecutors with the resources and support they need to do their jobs. The president requested a 3.7 percent increase in spending for the Drug Enforcement Administration (DEA) in his fiscal year 2018 budget.

5. We will close the shipping loopholes that China and others are exploiting to send dangerous drugs across our borders in the hands of our own postal service. In order to “close the shipping loophole,” experts say the first step is to digitally scan all postal packages that come into the United States. The U.S. Postal Service recently told Congress that they scan about half of all packages, but a bill introduced by Sen. Rob Portman would require the scanning of all packages. The White House supports this bill but the legislation has stalled in the Senate Finance Committee, where it has been for almost a year.

6. The FDA has been far too slow to approve abuse-deterring drugs. The Food and Drug Administration (FDA) approved the abuse deterrent drug RoxyBond in April. The FDA also took the historic step of removing the opioid Opana ER from the market specifically because of its addictive qualities.   

7. And when the FDA has approved these medications, the rules have been far too restrictive, severely limiting the number of authorized prescribers as well as the number of patients each doctor can treat. As president, I’d work to lift the cap on the number of patients that doctors can treat, provided they follow safe prescribing practices and proper treatment supervision.  The Obama Administration bumped the cap on the number of patients a doctor can treat from 200 to 275, but advocates say it should be at 500. The Trump Administration has not acted on this. 

8. At the same time, DEA should reduce the amount of Schedule II opioids (drugs like oxycodone, methadone and fentanyl) that can be made and sold in the U.S. In early August 2017, the DEA announced it is proposing to further reduce the amount of opioids that can be produced in the United States by 20 percent.

9. I would also expand incentives for states and local governments to use drug courts and mandated treatment. The Trump Administration has tried to take credit for steps for work that happened during the Obama Administration. “Trump Administration Awards Grants to States to Combat the Opioid Crisis” reads an April press release from the Department of Health and Human Services (HHS) that announced a $485 million infusion to the states. But the bipartisan bill authorizing that money was supported by Vice President Biden and signed by President Obama in 2016.  

10. I would dramatically expand access to treatment slots and end Medicaid policies that obstruct inpatient treatment. The president’s fiscal year 2018 budget requested an increase in drug treatment funding by $200 million to $10.8 billion, although advocates say even that number falls short. Health care reform bills supported by the White House cut Medicaid’s growth significantly, even though some 1.8 million people who got Medicaid through the Affordable Care Act rely on the program for drug abuse treatment. The president’s budget request for 2018 also called for a $167 million cut to drug abuse prevention.

11. I would dramatically expand first responders’ and caregivers’ access to Narcan, an antidote that treats overdoses and saves thousands of lives. When CBS News interviewed Richard Baum, the acting director of the Office of National Drug Control Policy in late July 2017, he said the administration has been “advocating for access to Narcan” but they “have a lot more work to do.”

12. I would also restore accountability to our Veterans Administration. Too many of our brave veterans have been prescribed these dangerous and addictive drugs by a VA that should have been paying them better attention.  In late June, 2017 President Trump signed the bipartisan bill Department of Veterans Affairs Accountability and Whistleblower Protection Act of 2017 that was supported by the Veterans of Foreign Wars. 

Since becoming president the President and administration officials have made other promises regarding the opioid crisis.  We are tracking them here as well.

13. On March 29th, the president announced the creation of an “opioid commission,” noting that an interim report would be produced by the end of June.  The commission didn’t meet for two months because of “scheduling delays” and the interim report was released a month late. It called for the president to declare the opioid crisis a “national emergency.” No word from the White House on whether that will happen.

14. Counselor to the President Kellyanne Conway told CBS News in mid-July that one of her goals was to “de-stigmatize addiction.” To date there has not been any initiatives announced on that front. 

 

 

What is CRO

A cro is a clinical research organization by contract. It is a type of company that offers its clinical studies management services to the pharmaceutical, biotechnology, and medical device manufacturers mainly. The management of a clinical study is more complicated than it might seem since many actors are involved (manufacturers, promoters, ethical committees, competent authorities, Centers, Foundations, Researchers, legal departments, patients). Also, they must work under the rules of Good Clinical Practice and the Harmonization Guidelines (GCP-ICH Guidelines) that ensure the quality of the study. Being able to have a CRO as a partner to rely on the management of the study is essential and in this case, the clinical research organization by contract acts as a bridge between the promoter, the one who hires the services, and the rest of the actors involved in the clinical study.

clinical research organization

Services offered by a CRO:

Traditionally, CROs have been responsible for the implementation and monitoring of clinical trials, but more and more companies that offer all the services associated with conducting a clinical study are considered “full-service CROs.” The services that a CRO can offer can be divided according to the phase in which you are in the study:

clinical research organization
  • The implementation includes the development and review of protocols for trials, the adaptation of the necessary documentation to the legislation, the obtaining of the necessary approvals from the clinical research ethics committees and regulatory authorities, the design and the preparation of the data collection notebooks, the determination of the sample, the selection of the best researchers and research centers and the final negotiation of the contracts.
  • Once approval is approved and the trial begins, the clinical research organization by contract offers its services for monitoring, which consists of monitoring compliance with the protocol and with the procedures established for the development of the study. Likewise, pharmacy vigilance services include detection and action in case of the occurrence of an Adverse Event.
  • The last steps to ensure the success of any clinical study are the management of data, the generation of reports and the control and storage of documentation. Throughout the study, work is carried out by Good Clinical Practices (BPC) that ensures the quality of the study.

 Types of CROs

There are different criteria to classify CROs:

  • If you take into account the level of specialization of the company, you can find companies specialized in a type of study (clinical trials, research with health products or observational studies) and also CROs specialized in a therapeutic area, such as oncology or ophthalmology.
  • Taking into account the geographical area in which they move, you can classify CROs as local or global. Global companies are usually large companies that have offices all over the world, their coverage is greater, but they are usually less flexible than local ones, whose knowledge of the country’s peculiarities is greater, but their coverage is usually not as wide.

Low Risk of Producing an Opioid Use Disorder in Primary Care by Prescribing Opioids to Prescreened Patients with Chronic Noncancer Pain.

Low Risk of Producing an Opioid Use Disorder in Primary Care by Prescribing Opioids to Prescreened Patients with Chronic Noncancer Pain.

https://www.ncbi.nlm.nih.gov/pubmed/28379504

Objective. :

To examine the risk of developing aberrant behaviors that might lead to a substance use disorder (addiction) when prescribing opioids for the relief of chronic noncancer pain in primary care settings.

Design. :

Longitudinal, prospective, descriptive design with repeated measures.

Setting. :

Private community-based internal medicine and family medicine clinics.

Subjects. :

Patients with chronic musculoskeletal pain.

Methods. :

Standardized measures of patient status (pain, functional impairment, psychiatric disorders, family history) and treatments provided, urine drug monitoring, and medical chart audits (presence of aberrant drug-related behaviors) were obtained in a cohort of 180 patients at the time of initiating opioids for chronic noncancer pain and at three, six, and 12 months thereafter.

Results. :

Over the 12-month follow-up period, subjects demonstrated stable, mild to moderate levels of depression (PHQ-9 scores ranging from 9.43 to 10.92), mild anxiety (BAI scores ranging from 11.80 to 14.67), minimal aberrant drug-related behaviors as assessed by chart reviews, and a low percentage of illicit drug use as revealed by results of urine drug monitoring. Less than 5% of our study population revealed any evidence of substance use disorder.

Conclusions. :

This prospective study suggests that patients without a recent or prior history of substance use disorder who were prescribed primarily short-acting opioids in low doses for chronic noncancer pain have a low risk for developing a substance use disorder. This finding supports the importance of prescreening patients being considered for opioid therapy and that prescription of opioids for noncancer pain may carry a lower risk of abuse in selected populations such as in private, community-based practices.

The Justice Department has dropped its appeal of a key disability rights lawsuit

Is This an ‘Ominous’ Message for the Disabled Under Trump?

http://www.thedailybeast.com/is-this-an-ominous-message-for-the-disabled-under-trump

The sudden dismissal of an Americans with Disabilities Act lawsuit in Virginia has advocates concerned that a systematic weakening of the federal law has begun.

The Justice Department has dropped its appeal of a key disability rights lawsuit—and advocates say they fear this means people with disabilities could see their rights rolled back under President Donald Trump.

The lawsuit at issue is in Richmond, Virginia, where a sheriff’s deputy, Emily Hall, had to temporarily leave her job to get surgery for a heart condition in September 2012. After her surgery, she tried to return to work but wasn’t physically capable of taking her old position. The sheriff’s department told her she could apply for a less strenuous job. When she applied, she didn’t get that position, according to court documents.

So Hall sued the sheriff’s department, charging it violated the Americans with Disabilities Act (ADA) by failing to accommodate her disability. The Justice Department initially joined her effort. Then-Attorney General Loretta Lynch, Civil Rights Division head Vanita Gupta, and U.S. Attorney Dana Boente—now a senior DOJ official under Attorney General Jeff Sessions—all signed on.

When a federal judge in Virginia ruled that the sheriff hadn’t violated Hall’s rights, Hall and the Justice Department appealed the ruling to the Fourth Circuit Court of appeals.

But on July 28, the Justice Department moved to dismiss its own appeal, and the court granted the dismissal.

Top officials who worked in the Civil Rights Division under Obama say that may be an ominous sign—an indicator that Sessions’ Justice Department may be far less aggressive in defending the rights of people with disabilities than President Barack Obama’s. They fear the dismissal could be the beginning of a shift away from the prior administration’s energetic stance.

“I’m very pessimistic,” said Sam Bagenstos, who was second-in-command in the Civil Rights Division during the Obama administration. “I think this administration is likely to slow down very substantially their enforcement of the ADA. But I’d like to be proven wrong.”

The Justice Department has already changed its position on some voting rights litigation and is reconsidering the Obama-era efforts to make troubled local police departments change their practices.

Lauren Ehrsam, a spokesperson for the Justice Department, said it is firmly committed to enforcing the ADA.

“This administration and Department of Justice are strongly committed to protecting the rights of people with disabilities,” she said, noting that since January the department has entered 17 settlement agreements around the country to help people with disabilities go to restaurants, vote in polling places, and communicate with doctors.

But disability rights’ advocates say they’re worried the department is moving in the wrong direction.

“It’s unfortunate and worrisome that the Civil Rights Division, having come this far, chose to suddenly withdraw its appeal from this terribly reasoned decision,” said Sasha Samberg-Champion, formerly a top attorney in the division during Obama’s presidency. “With the division currently staking out retrograde positions on LGBT issues, racial diversity in education, and elsewhere, disability rights advocates are watching closely to see whether the division will continue to forcefully protect the rights of people with disabilities such as Ms. Hall. The decision not to pursue her case further is grounds for concern.”

Bagenstos added that this case could be a leading indicator that Trump’s Justice Department could handle disability issues quite differently from Obama’s.

“It’s a very troubling data point,” he said. “It creates a lot of doubts under that the DOJ under Sessions will vigorously enforce the ADA. But a lot remains to be seen.”

Business groups—which argue the Justice Department sometimes takes too broad a view of the ADA—could be pleased with some changes.

Karen Harned, an attorney at the National Federation of Independent Businesses, said her group doesn’t believe companies should be required to give new jobs to employees who get disabilities while working there. She said her group’s view is that while employees in Hall’s situation should be able to apply for jobs that could accommodate them, they shouldn’t necessarily have a right to those positions.

“It’s good to see that they’re not trying to push a theory that has already been rejected by other courts,” she said, citing the fact that some circuit courts have rejected similar lawsuits. “If a statute doesn’t say it clearly, small business owners shouldn’t be held to these new crazy theories.”

During the Obama administration, the Civil Rights Division moved to aggressively enforce the ADA—looking to craft new regulations on businesses and bringing lawsuits based on a broad view of their jurisdiction. Disability rights advocates say they hope Sessions’ Justice Department will be just as aggressive.

Trump’s record on disability rights won’t reassure them, as Trump companies have faced numerous lawsuits alleging they didn’t accommodate people with disabilities.

“We are watching them very closely to make sure they continue the aggressive enforcement of the ADA despite the change in administration,” said Curt Decker, who heads the National Disability Rights Network. “The issues have not changed. The need for protection for people with disabilities remains the same.”

Doubled Since 2007, Hitting a 40-Year High – where is the media coverage ?

Teen Girl Suicides Doubled Since 2007, Hitting a 40-Year High

http://www.acsh.org/news/2017/08/03/teen-girl-suicides-doubled-2007-hitting-40-year-high-11651

It’s not easy being a teenager. Since time immemorial, teens have had to grapple with the raging hormones and quest for self-identity that are hallmarks of this stage of life. However, coming of age in an era of social media — in which every moment of a person’s life can be live-tweeted and publicly scrutinized — makes an already difficult situation that much worse.

New data released by the CDC highlights the hardship of modern teenage life. Since 2007, the suicide rate among boys aged 15 to 19 has increased by 31% (from 10.8 to 14.2 per 100,000), while the suicide rate among girls has more than doubled (from 2.4 to 5.1 per 100,000). In fact, the suicide rate for teenage girls is at a 40-year high*.

The authors do not explain the reasons behind this increase, but it is tempting to speculate that social media may be playing a role. Facebook was founded in 2004, Twitter in 2006. Over the past several years, multiple anecdotes have linked teenage suicides to social media bullying.

Of course, anecdotes are not data. A closer examination into the cause of this recent surge in teen suicides is needed. However, linking them to social media is certainly a tempting hypothesis.

Suicide Is Not Just a Problem for Teens

Complicating the picture is the fact that, according to other data from the CDC, suicide rates have increased for all age groups in the United States, with the lone exception of those aged 75 and older. The surge in suicides for people in their 60s, for instance, is not likely attributable to social media.

Additionally, rural Americans have been hit hardest by the suicide epidemic, witnessing an increase of 40% in 16 years. Once again, this would argue against social media as an explanation.

What Is Causing the Surge in Suicides?

Obviously, people commit suicide for various reasons: Depression, loneliness, mental illness, drug addiction, relationship trouble, financial hardship, and bullying have all been implicated. Determining the predominant causes of suicide in each age and ethnic demographic would be a major step toward reversing this troubling trend.

Note: The data in this study only goes back 40 years. The current 40-year high could actually stretch back further in time.

Source: “QuickStats: Suicide Rates for Teens Aged 15-19 Years, by Sex — United States, 1975-2015.” MMWR 66 (30): 816. Published: 4-Aug-2017. DOI: 10.15585/mmwr.mm6630a6.